References
- Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397–405.
- Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. Plos One 2011;6:e17948.
- Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: A retrospective case series. J Neurooncol 2013;114:237–40.
- Lee EQ, Ruland S, LeBoeuf NR, Wen PY, Santagata S. Successful treatment of a progressive BRAF V600E–mutated anaplastic pleomorphic xanthoastrocytoma. J Clin Oncol 2014;32, published ahead of print
- Harada S, Fallon KB, Reddy A, Nabors LB. Molecular pathology: SC18-1. Interesting case-actionable mutation in a case with a recurrent pleomorphic xanthoastroctoma with anaplastic features. Pathology 2014;46(Suppl 2):S28–9.
- Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 2014; 14:258.